The Interpretation of Animal Studies A million years ago, as far as we can guess from studies of present-day primitive people, the sexually mature human female would have been continually either pregnant or lactating while taboos kept males at bay and they vented their lust by indulging in polygamy. The very occurrence of a menstrual period might have been as much a matter for concern among primitive ladies as a failure to menstruate is for many women today.
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Less than a hundred years ago the ancestral mother of the laboratory rat would also have spent most of her time either pregnant or lactating except that, depending on climate and food supply, &c., there would have been seasons when she was sexually quiescent without anything happening at all.
Women who have no babies are more prone to mammary cancer than those who have them. Abstinence from sexual relations is associated with enhanced risk of endometrial pathology in theform of fibroids and endometrial cancer. But, as is only right, the well-behaved nun wins on balance because lack of sexual intercourse is associated with much-reduced risk of cancer of the uterine cervix.
The problems of female laboratory rats appear to be much greater and more complex than those of nuns. rn later life endometrial hyperplasia, often with cyst formation, is so common that it is difficult to decide what a 'normal' rat uterus should look like. In many strains of rat the incidence of mammary tumours rises to virtually 100% in old ageand this means a lot of tumours because rats have more breasts than do nuns.
Most of the tumours are benign fibroadenomas, but from these, by a process called 'tumourprogression' by the late Dr Leslie Foulds, malignant adenocarcinomas occasionally arise. But the saga of the female laboratory rat's endocrine problems does not end with uterine and mammary changes. In many strains chromophobe adenomas of the pituitary gland rise to a very high incidence with age, and ovarian, adrenal and thyroid tumours abound.
There is, however, one important difference between the environment of the average nun and that of the laboratory female rat. The former is, as a rule, required to be abstemious in how much she eats, but the well-meaning laboratory animal house-keeper provides his female rats with a superabundance of a highly nutritious diet which they can nibble away at all night and all day. In consequence laboratory rats tend to be grossly overweight with all their internal organs buried in adipose tissue. Almost certainly overfeeding contributes to the risk of development of all sorts of tumours in rats and mice. And there are several authoritative accounts of the reduction of mammary tumour incidence in rats and mice in response to relatively slight dietary restriction.
No epidemiologist would choose a convent for a study on oral contraceptives. Is it not rather extraordinary, therefore, that any regulatory authority should require long-term tests on cloistered laboratory female rats for the purpose of seeing whether the use of oral contraceptives by women is likely to increase their risk of developing any form of cancer? And yet it is precisely this which the Committee on Safety of Medicines demanded of manufacturers of oral contraceptives (OC) several years ago.
Before the series of tests on OCs were asked for by the Committee on Safety of Medicines (1972) a lot was known about the effects of cestrogens and progesterones on laboratory animals. The risk of development of a wide variety of tumours was known to be increased by cestrogens. The list included liver cell tumours in rats and vaginal and cervical tumours in mice. Experiments had been undertaken in mice in which one ovary was removed and the other was implanted into the 9 349
Proc. roy. Soc. Med. Volume 69 May 1976 spleen. The result was that the cestrogens produced by the ovary in the spleen went straight to the liver and were destroyed there on the first pass. No cestrogen reached the pituitary with the consequence that the gland went on producing follicle-stimulating hormone (FSH). In the end, tumours arose both in the ovary and in the pituitary and the liver became engorged with blood producing a picture described by pathologists as 'peliosis hepatis'. It was also known that in many strains of mice liver cell tumours arise in up to 100 % of untreated control animals before they die. As a rule the incidence is higher in males than in females and feminization, involving castration and the administration of exogenous cestrogen, actually reduces the risk of liver tumour development in the males. The effects of stress have also to be considered. Recently, Riley (1975) reported that stress increased mammary tumour incidence in mice carrying the Bittner mammary tumour virus. My colleagues and I (Davis et al. 1975), however, found that stress significantly reduced mammary tumour incidence in rats.
The position can perhaps best be summarized as follows: Given the results of studies of the effects of cestrogens in mice it would not be possible to predict how exposure of rats to oestrogens is likely to affect the incidence of various types of cancer. A fortiori one cannot expect to be able to predict from studies on laboratory rodents how the administration of oral contraceptives is likely to affect the incidence of various kinds of cancer in women.
Since 1972, there have been several reports of liver tumours in women taking oral contraceptives. It is reasonable to ask if these are likely to be the human counterpart of the liver tumours seen in rats exposed to oral contraceptive preparations. Also since 1972 we have been made aware of the risk of structural and pathological changes in the vagina and uterine cervix in the daughters of women given very high doses of cestrogens (usually diethylstilboestrol) during pregnancy. It is not widely appreciated that somewhat analogous genital tract changes were described in cestrogentreated mice by Gardner (1959) and by Dunn & Green ( 963) .
Personally, I believe that the administration of massive doses of cestrogens during pregnancy for the treatment of threatened or habitual abortion constituted an irresponsible act by the clinicians concerned. However, I do not believe that the occurrence of vaginal cancers in the daughters of women given massive doses of stilbcestrol during pregnancy tells us anything useful about the risk of cancer in women taking oral contraceptives containing much smaller amounts of uestrogen.
It is possible to argue that one is likely to obtain more reliable information about the prob-10 able effects on cancer incidence in women taking the pill from studies on non-human primates whose reproductive physiology is more similar to man's than is that of other species. However, it is generally agreed that meaningful carcinogenicity tests require the study for the major part of the life span of relatively large numbers of in/dividuals. If higher apes were used, the studies would be prohibitively expensive and the results would take perhaps twenty years to get. More importantly, the study of carcinogenicity requires a large body of background information concerning the species used. In particular one needs to know the incidence of spontaneous neoplasms of various kinds and if possible the spectrum of oncogenic viruses to which the species is prey. This kind of information hardly exists for the higher apes and even if it did I for one would be wholly opposed to plundering the jungles for such animals to use for large-scale carcinogenicity tests. Higher apes undoubtedly have an important role to play in the development of new oral contraceptives, in studies on mechanisms of action, and in initial studies of safety and toxicity. They should not be used in large numbers in attempts to predict carcinogenicity.
Theoretically, hormones may increase cancer risk either because of their hormonal activity or because they are for some reason intrinsically carcinogenic. In the case of the pill it would be my view that cancer risk because of hormonal activity can only be meaningfully studied in humans by epidemiological methods. The chemical structure of most of the ingredients of contraceptive pills makes it rather unlikely that they can have intrinsic carcinogenicity. It was presumably the real purpose of the tests required by the Committee on Safety of Medicines to make sure that the materials tested did not have intrinsic carcinogenicity. Reading between the lines of the Committee's report, I believe that this purpose was achieved. Despite all that I have said I agree that the exclusion of intrinsic carcinogenicity is desirable and I see no better way of doing this than by large-scale long-term tests on laboratory rodents. My main quarrel with the report of the Committee on Safety of Medicines is not that such tests were carried out, but that it was presumed that the results provided reassurance tljat the hormonal effects of the substances tested would not influence cancer risk in women. Tragically, Dr John Barnes of the Medical Research Council's Toxicology Unit died last week. He of all people deplored the wastage of resources on ill-conceived animal tests and the lack of interest in studies of mechanisms in toxicology. After the report of the Committee on Safety of Medicines was published he wrote (Barnes 1972) to the British Medical Jouirnlal to say that he found it difficult to see how the Committee reached its conclusion that the animal evidence 'cannot be interpreted as constituting a carcinogenic hazard to women when these preparations are used as oral contraceptives'. 
Oral Contraceptives and Liver Tumours
In October 1973 Baum and her colleagues described 7 cases of hepatic adenoma which had occurred in women who were taking oral contraceptives. Five of their patients were in their 20s and the oldest of the series was 39 years of age. On the basis of this relatively large number of cases of a previously rare lesion, Baum et al. suggested that oral contraceptives might be partly or wholly the cause of the hepatic adenomas in these patients. Over the following six months reports of 4 cases of hepatic adenomas occurring in women on the pill were published (Contostavlos 1973 , Knapp & Ruebner 1974 , Kelso 1974 , Horvath et al. 1974 . Unfortunately none of these accounts had an adequate histological description of the lesions and there were no photographs of the microscopical appearances.
In the middle of 1974 two papers appeared at about the same time reporting the occurrence of a rather different liver lesion in women on oral contraceptives. Mays' group in the United States reported 4 cases of what they called 'focal nodular hyperplasia' in women who had taken the pill (Mays et al. 1974) . The British paper (O'Sullivan & Wilding 1974) described 3 cases of 'liver hamartomas' in similar patients. It is likely that these conditions differ only in name, and it is convenient to consider examples of both under the name 'focal nodular hyperplasia'. Whatever the nature of the lesions, there is no doubt that it is a different entity from hepatic adenoma. So at this point two distinct conditions, both previously uncommon, had been reported in moderate numbers in patients on the pill.
During the rest of 1974 a few more cases of hepatic adenomas in patients on oral contra-ceptives were described. Berg et al. (1974) Although it is not stated in their account it is probable that 3 of their cases appeared in Baum's original paper (1973) . They first read their paper at a surgical meeting, and 2 more similar cases were recalled by members of the audience in the discussion. Two cases of focal noduiar hyperplasia of liver in women on the pill were reported from Australia by O'Reilly (1975) who pointed out that in 2 of his previous cases (O'Reilly 1974) the patients were also women on oral contraceptives. A further 3 cases were described from Canada (Fisher et al. 1975 , Shojania & Hogg 1975 and another example of focal nodular hyperplasia in a woman who had been on the pill appeared from Sweden (Zurbriggen & Tylen 1975) . Baum (1975) referred to 6 cases additional to her original 7, but it is not clear that these are different from the patients reported by Ameriks et al. (1975) . In August, Christopherson et al. (1975) added a further 7 cases of focal nodular hyperplasia and one hepatic adenoma in women who had taken oral contraceptives. In addition this group has seen a hepatocellular carcinoma in a young woman on the pill. Thus, about 50 cases of benign liver nodules have been reported in women who have taken oral contraceptives. They have, in general, presented in one of four ways: as an incidental finding at laparotomy, often for cholecystectomy; as a lump felt by the patient; as vague gastrointestinal symptoms; and, most seriously, as haemoperitoneum. A number of patients have died because the lesion has bled into the peritoneal cavity. Macroscopically there is a well-circumscribed tumour, often yellow-tan in colour, and usually single, although there may be two or even more in the liver. In focal nodular hyperplasia there is often a central scar. This is not a feature of hepatic adenoma. However, the scar may not be obvious and it is not always possible to make the diagnosis on naked-eye examination alone.
Histologically there are two entities (Phillips et al. 1973) . The hepatic adenoma is a benign neoplasm which consists of well-differentiated hepato-
